Related Experiment Video
Updated: Aug 14, 2026
09:50
Experimental Methods for Testing the Effects of Neurotrophic Peptide, ADNF-9, Against Alcohol-induced Apoptosis during Pregnancy in C57BL/6 Mice
Published on: April 24, 2013
Inhibition of human neuroblastoma growth by a specific VIP antagonist
G Lilling1, Y Wollman, M N Goldstein
1Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Israel.
Journal of Molecular Neuroscience : MN
|January 1, 1994
Summary
Vasoactive intestinal peptide (VIP) fuels neuroblastoma growth, acting as an autocrine factor. A novel VIP antagonist effectively inhibited neuroblastoma cell proliferation, suggesting a new cancer treatment strategy.
Area of Science:
- Neuroscience
- Oncology
- Molecular Biology
Background:
- Vasoactive intestinal peptide (VIP) is a neuropeptide crucial for embryonic development and brain growth.
- VIP also exhibits mitogenic properties for tumor cells, including human neuroblastoma (NMB).
- Previous studies detected VIP mRNA transcripts in neuroblastoma cells.
Purpose of the Study:
- To investigate the role of VIP in neuroblastoma growth.
- To evaluate the efficacy of a VIP hybrid antagonist in inhibiting neuroblastoma proliferation.
Main Methods:
- Northern blot analysis to detect VIP mRNA.
- Measurement of VIP-like immunoreactivity in neuroblastoma cells and culture medium.
- Receptor binding assays using [125I]-VIP.
- Assessment of cell proliferation via thymidine incorporation and cell counts.
Main Results:
- VIP-like immunoreactivity was found in neuroblastoma cells, increasing with growth and decreasing at confluency.
- Neuroblastoma cells secreted VIP-like immunoreactivity into the medium, suggesting autocrine signaling.
- A VIP hybrid antagonist displaced [125I]-VIP binding and dose-dependently inhibited neuroblastoma cell multiplication.
Conclusions:
- VIP appears to play an autocrine role in regulating neuroblastoma growth.
- VIP signaling is a potential therapeutic target for neuroblastoma and other neuronal-derived tumors.
- VIP hybrid antagonists show promise for inhibiting neuroblastoma proliferation.
